 Christopher Lieu
Concepts (338)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 33 | 2022 | 584 | 7.010 |
Why?
| | Molecular Targeted Therapy | 9 | 2019 | 380 | 2.420 |
Why?
| | Antineoplastic Agents | 13 | 2021 | 2071 | 2.340 |
Why?
| | Biomarkers, Tumor | 14 | 2022 | 1045 | 2.160 |
Why?
| | Neoplasms | 11 | 2022 | 2037 | 1.470 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 12 | 2021 | 1397 | 1.450 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2019 | 681 | 1.290 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 517 | 1.070 |
Why?
| | Colonic Neoplasms | 4 | 2021 | 226 | 1.070 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 241 | 1.030 |
Why?
| | Bevacizumab | 4 | 2020 | 124 | 1.020 |
Why?
| | Mutation | 11 | 2020 | 3447 | 0.910 |
Why?
| | Neuroendocrine Tumors | 5 | 2022 | 71 | 0.910 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2020 | 634 | 0.830 |
Why?
| | Age of Onset | 7 | 2022 | 494 | 0.800 |
Why?
| | Piperidines | 2 | 2017 | 176 | 0.750 |
Why?
| | Colectomy | 1 | 2019 | 77 | 0.740 |
Why?
| | Neoplasm Staging | 9 | 2021 | 1226 | 0.740 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 304 | 0.730 |
Why?
| | Cetuximab | 2 | 2020 | 95 | 0.710 |
Why?
| | Cyclosporine | 1 | 2018 | 186 | 0.700 |
Why?
| | Azetidines | 1 | 2017 | 38 | 0.680 |
Why?
| | Terminology as Topic | 1 | 2019 | 229 | 0.680 |
Why?
| | Benzimidazoles | 1 | 2018 | 147 | 0.680 |
Why?
| | Appendiceal Neoplasms | 2 | 2020 | 15 | 0.670 |
Why?
| | Microsatellite Instability | 5 | 2021 | 26 | 0.650 |
Why?
| | Disease-Free Survival | 6 | 2019 | 682 | 0.620 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 74 | 0.610 |
Why?
| | Healthcare Disparities | 1 | 2021 | 465 | 0.610 |
Why?
| | Patient Rights | 1 | 2015 | 9 | 0.590 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 71 | 0.590 |
Why?
| | Precision Medicine | 1 | 2019 | 315 | 0.590 |
Why?
| | Pyrimidinones | 1 | 2015 | 89 | 0.590 |
Why?
| | Genetic Predisposition to Disease | 3 | 2022 | 2424 | 0.590 |
Why?
| | Therapies, Investigational | 1 | 2015 | 16 | 0.580 |
Why?
| | Drug and Narcotic Control | 1 | 2015 | 30 | 0.580 |
Why?
| | Drugs, Investigational | 1 | 2015 | 22 | 0.580 |
Why?
| | Pyridones | 1 | 2015 | 107 | 0.570 |
Why?
| | Humans | 66 | 2022 | 113846 | 0.560 |
Why?
| | Neovascularization, Pathologic | 2 | 2013 | 291 | 0.550 |
Why?
| | Rectal Neoplasms | 3 | 2020 | 102 | 0.550 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 140 | 0.540 |
Why?
| | Pyrazines | 2 | 2018 | 86 | 0.530 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 192 | 0.500 |
Why?
| | Immunoglobulin G | 1 | 2017 | 798 | 0.490 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2020 | 205 | 0.480 |
Why?
| | Drug Design | 1 | 2013 | 177 | 0.480 |
Why?
| | Terminal Care | 1 | 2015 | 205 | 0.460 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2011 | 3 | 0.460 |
Why?
| | Middle Aged | 29 | 2021 | 28753 | 0.460 |
Why?
| | Neoplasm Metastasis | 7 | 2022 | 616 | 0.450 |
Why?
| | ErbB Receptors | 4 | 2017 | 549 | 0.440 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2013 | 346 | 0.440 |
Why?
| | Immunotherapy | 3 | 2021 | 462 | 0.430 |
Why?
| | Fibroblast Growth Factors | 1 | 2011 | 176 | 0.410 |
Why?
| | Adult | 27 | 2022 | 31979 | 0.400 |
Why?
| | src-Family Kinases | 1 | 2010 | 96 | 0.400 |
Why?
| | Stomach Neoplasms | 3 | 2022 | 74 | 0.390 |
Why?
| | Aged | 22 | 2022 | 20109 | 0.380 |
Why?
| | Patient Selection | 3 | 2019 | 694 | 0.380 |
Why?
| | Pancreatic Neoplasms | 4 | 2022 | 744 | 0.370 |
Why?
| | Boronic Acids | 1 | 2008 | 44 | 0.370 |
Why?
| | Health Services Accessibility | 1 | 2015 | 777 | 0.360 |
Why?
| | Etoposide | 1 | 2008 | 166 | 0.360 |
Why?
| | Medical Oncology | 3 | 2021 | 189 | 0.360 |
Why?
| | Carboplatin | 1 | 2008 | 138 | 0.360 |
Why?
| | Disease Management | 4 | 2021 | 606 | 0.350 |
Why?
| | Adenocarcinoma | 3 | 2021 | 804 | 0.350 |
Why?
| | Clinical Decision-Making | 3 | 2019 | 274 | 0.350 |
Why?
| | Genomics | 3 | 2022 | 626 | 0.340 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2021 | 788 | 0.340 |
Why?
| | Shock, Septic | 1 | 2009 | 190 | 0.330 |
Why?
| | Kaplan-Meier Estimate | 6 | 2017 | 872 | 0.330 |
Why?
| | Pathology, Molecular | 2 | 2017 | 26 | 0.330 |
Why?
| | Pathology, Clinical | 2 | 2017 | 36 | 0.330 |
Why?
| | Drug Administration Schedule | 4 | 2019 | 825 | 0.310 |
Why?
| | ras Proteins | 2 | 2017 | 155 | 0.310 |
Why?
| | Male | 28 | 2022 | 60993 | 0.310 |
Why?
| | Clinical Trials as Topic | 3 | 2015 | 1009 | 0.290 |
Why?
| | Female | 28 | 2021 | 63035 | 0.290 |
Why?
| | Age Factors | 5 | 2021 | 3330 | 0.280 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1432 | 0.280 |
Why?
| | Ovarian Neoplasms | 2 | 2020 | 341 | 0.280 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2021 | 325 | 0.270 |
Why?
| | United States | 12 | 2021 | 12329 | 0.260 |
Why?
| | Antibodies, Monoclonal | 4 | 2019 | 1302 | 0.260 |
Why?
| | Signal Transduction | 6 | 2018 | 4923 | 0.240 |
Why?
| | Genetic Testing | 3 | 2022 | 382 | 0.240 |
Why?
| | Disease Models, Animal | 4 | 2021 | 3910 | 0.230 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2022 | 52 | 0.230 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 31 | 0.230 |
Why?
| | Neoadjuvant Therapy | 3 | 2021 | 288 | 0.230 |
Why?
| | Membrane Proteins | 3 | 2019 | 1098 | 0.230 |
Why?
| | Pheochromocytoma | 1 | 2022 | 53 | 0.220 |
Why?
| | Health Status Disparities | 2 | 2020 | 220 | 0.220 |
Why?
| | Meningioma | 1 | 2022 | 72 | 0.220 |
Why?
| | Congresses as Topic | 2 | 2019 | 209 | 0.210 |
Why?
| | Heterografts | 1 | 2021 | 126 | 0.210 |
Why?
| | Circulating Tumor DNA | 1 | 2020 | 18 | 0.210 |
Why?
| | Consensus | 2 | 2019 | 427 | 0.200 |
Why?
| | Practice Patterns, Physicians' | 1 | 2009 | 1214 | 0.200 |
Why?
| | Treatment Outcome | 10 | 2021 | 9002 | 0.200 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2019 | 17 | 0.200 |
Why?
| | Smad4 Protein | 1 | 2019 | 35 | 0.200 |
Why?
| | Immune System | 1 | 2021 | 198 | 0.200 |
Why?
| | GTP Phosphohydrolases | 1 | 2019 | 63 | 0.200 |
Why?
| | Retinal Vein | 1 | 2019 | 7 | 0.200 |
Why?
| | African Americans | 2 | 2020 | 1101 | 0.200 |
Why?
| | Area Under Curve | 2 | 2018 | 328 | 0.190 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 74 | 0.190 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2019 | 23 | 0.190 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 56 | 0.190 |
Why?
| | Camptothecin | 2 | 2017 | 87 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 132 | 0.190 |
Why?
| | Disease Progression | 4 | 2017 | 2489 | 0.190 |
Why?
| | Survivorship | 1 | 2018 | 24 | 0.180 |
Why?
| | Survival Rate | 5 | 2021 | 1854 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2018 | 76 | 0.180 |
Why?
| | Esophageal Neoplasms | 1 | 2021 | 222 | 0.180 |
Why?
| | Retinal Diseases | 1 | 2019 | 71 | 0.180 |
Why?
| | Neoplasm Grading | 1 | 2019 | 252 | 0.180 |
Why?
| | Genes, ras | 1 | 2018 | 98 | 0.180 |
Why?
| | Vasculitis | 1 | 2019 | 87 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2229 | 0.180 |
Why?
| | Cohort Studies | 6 | 2020 | 5011 | 0.180 |
Why?
| | Patient Advocacy | 1 | 2018 | 68 | 0.180 |
Why?
| | Risk Factors | 6 | 2022 | 9050 | 0.180 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1141 | 0.180 |
Why?
| | Acneiform Eruptions | 1 | 2017 | 1 | 0.180 |
Why?
| | Asthenia | 1 | 2017 | 2 | 0.180 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 268 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2470 | 0.170 |
Why?
| | Drug Eruptions | 1 | 2017 | 26 | 0.170 |
Why?
| | Hypokalemia | 1 | 2017 | 32 | 0.170 |
Why?
| | Population Surveillance | 1 | 2021 | 439 | 0.170 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 44 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 201 | 0.170 |
Why?
| | Risk Assessment | 2 | 2019 | 3147 | 0.170 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 37 | 0.170 |
Why?
| | Evidence-Based Medicine | 2 | 2019 | 728 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 182 | 0.170 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2017 | 72 | 0.170 |
Why?
| | Imidazoles | 1 | 2018 | 259 | 0.170 |
Why?
| | Patient Compliance | 1 | 2021 | 604 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 154 | 0.160 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 7 | 0.160 |
Why?
| | Hospitals | 1 | 2021 | 468 | 0.160 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2015 | 378 | 0.160 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 151 | 0.160 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2018 | 280 | 0.160 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6796 | 0.160 |
Why?
| | Edema | 1 | 2016 | 116 | 0.160 |
Why?
| | Diabetic Neuropathies | 1 | 2016 | 79 | 0.160 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 22 | 0.160 |
Why?
| | Capecitabine | 1 | 2015 | 43 | 0.160 |
Why?
| | GPI-Linked Proteins | 1 | 2016 | 59 | 0.160 |
Why?
| | Databases, Factual | 3 | 2017 | 1206 | 0.150 |
Why?
| | Prognosis | 7 | 2020 | 3544 | 0.150 |
Why?
| | Analgesics | 1 | 2016 | 157 | 0.150 |
Why?
| | Device Approval | 1 | 2015 | 22 | 0.150 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 232 | 0.150 |
Why?
| | Time Factors | 2 | 2019 | 7060 | 0.150 |
Why?
| | Receptor, Notch1 | 1 | 2015 | 66 | 0.150 |
Why?
| | Cancer Survivors | 1 | 2018 | 153 | 0.150 |
Why?
| | Patient Care Planning | 1 | 2016 | 166 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 465 | 0.150 |
Why?
| | Prevalence | 1 | 2022 | 2407 | 0.150 |
Why?
| | Animals | 9 | 2021 | 35394 | 0.140 |
Why?
| | Neuralgia | 1 | 2016 | 143 | 0.140 |
Why?
| | Deoxycytidine | 1 | 2015 | 146 | 0.140 |
Why?
| | Immunoblotting | 1 | 2015 | 375 | 0.140 |
Why?
| | Pancreas | 1 | 2017 | 262 | 0.140 |
Why?
| | Health Behavior | 1 | 2020 | 716 | 0.140 |
Why?
| | Gene Dosage | 1 | 2015 | 148 | 0.140 |
Why?
| | Drug Approval | 1 | 2015 | 72 | 0.140 |
Why?
| | Spinal Cord Injuries | 1 | 2016 | 153 | 0.140 |
Why?
| | Administration, Oral | 1 | 2017 | 798 | 0.140 |
Why?
| | Immunoconjugates | 1 | 2016 | 93 | 0.140 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 159 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2018 | 454 | 0.140 |
Why?
| | Delivery of Health Care | 1 | 2021 | 695 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 179 | 0.140 |
Why?
| | Quinazolines | 1 | 2015 | 244 | 0.140 |
Why?
| | Phenotype | 2 | 2021 | 3050 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 789 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1136 | 0.130 |
Why?
| | Genetic Variation | 1 | 2019 | 991 | 0.130 |
Why?
| | beta Catenin | 1 | 2015 | 228 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 835 | 0.130 |
Why?
| | Lymphocytes | 1 | 2015 | 392 | 0.130 |
Why?
| | Registries | 1 | 2021 | 1824 | 0.120 |
Why?
| | Patient-Centered Care | 1 | 2018 | 477 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 1 | 2017 | 716 | 0.120 |
Why?
| | Drug Combinations | 1 | 2013 | 300 | 0.120 |
Why?
| | Ligands | 1 | 2013 | 532 | 0.120 |
Why?
| | Cell Line, Tumor | 2 | 2019 | 2936 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 858 | 0.110 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 224 | 0.110 |
Why?
| | Patient Care Team | 1 | 2016 | 532 | 0.110 |
Why?
| | Risk | 1 | 2014 | 943 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2021 | 11340 | 0.110 |
Why?
| | Transcriptome | 1 | 2015 | 692 | 0.100 |
Why?
| | Streptococcaceae | 1 | 2009 | 2 | 0.100 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 450 | 0.100 |
Why?
| | Clinical Medicine | 1 | 2009 | 20 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2013 | 602 | 0.100 |
Why?
| | Myositis | 1 | 2009 | 42 | 0.100 |
Why?
| | Cytokines | 2 | 2015 | 1981 | 0.090 |
Why?
| | Sulindac | 1 | 2008 | 18 | 0.090 |
Why?
| | Bortezomib | 1 | 2008 | 49 | 0.090 |
Why?
| | Neutrophils | 1 | 2015 | 1324 | 0.090 |
Why?
| | Young Adult | 3 | 2020 | 10971 | 0.090 |
Why?
| | Mutation Rate | 2 | 2019 | 25 | 0.090 |
Why?
| | Maximum Tolerated Dose | 1 | 2008 | 187 | 0.090 |
Why?
| | Nausea | 1 | 2008 | 116 | 0.090 |
Why?
| | Neutropenia | 1 | 2008 | 133 | 0.090 |
Why?
| | Mice | 4 | 2021 | 15641 | 0.090 |
Why?
| | Prospective Studies | 2 | 2017 | 6250 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1243 | 0.090 |
Why?
| | Fluphenazine | 1 | 2007 | 5 | 0.090 |
Why?
| | Risperidone | 1 | 2007 | 25 | 0.090 |
Why?
| | Leucovorin | 2 | 2021 | 42 | 0.090 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 49 | 0.080 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1599 | 0.080 |
Why?
| | Anemia | 1 | 2008 | 166 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 1004 | 0.080 |
Why?
| | Fluorouracil | 2 | 2021 | 139 | 0.080 |
Why?
| | Gastrectomy | 2 | 2017 | 78 | 0.080 |
Why?
| | Fasting | 1 | 2008 | 280 | 0.080 |
Why?
| | Food | 1 | 2008 | 163 | 0.080 |
Why?
| | Thrombocytopenia | 1 | 2008 | 184 | 0.080 |
Why?
| | Propensity Score | 2 | 2017 | 226 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2017 | 2116 | 0.080 |
Why?
| | Frontal Lobe | 1 | 2007 | 168 | 0.080 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 198 | 0.070 |
Why?
| | Adolescent | 3 | 2020 | 18736 | 0.070 |
Why?
| | Survival Analysis | 2 | 2017 | 1414 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2010 | 1244 | 0.060 |
Why?
| | Apoptosis | 2 | 2015 | 2675 | 0.060 |
Why?
| | Receptors, Peptide | 1 | 2022 | 27 | 0.060 |
Why?
| | Intestinal Neoplasms | 1 | 2022 | 25 | 0.060 |
Why?
| | Radioisotopes | 1 | 2022 | 41 | 0.060 |
Why?
| | Gallium Radioisotopes | 1 | 2022 | 22 | 0.060 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 159 | 0.060 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 28 | 0.060 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 72 | 0.060 |
Why?
| | Europe | 1 | 2022 | 351 | 0.060 |
Why?
| | North America | 1 | 2022 | 274 | 0.060 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.060 |
Why?
| | Preventive Medicine | 1 | 2021 | 40 | 0.060 |
Why?
| | Canada | 1 | 2022 | 336 | 0.060 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 63 | 0.060 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 88 | 0.050 |
Why?
| | Liquid Biopsy | 1 | 2020 | 6 | 0.050 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2020 | 35 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2022 | 207 | 0.050 |
Why?
| | Morbidity | 1 | 2021 | 259 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 363 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 84 | 0.050 |
Why?
| | Geography | 1 | 2020 | 199 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 301 | 0.050 |
Why?
| | SEER Program | 1 | 2020 | 211 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 564 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 268 | 0.050 |
Why?
| | Spectrophotometry, Infrared | 1 | 2019 | 91 | 0.050 |
Why?
| | District of Columbia | 1 | 2018 | 18 | 0.050 |
Why?
| | Karnofsky Performance Status | 1 | 2018 | 38 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 26 | 0.050 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 109 | 0.050 |
Why?
| | Colon | 1 | 2020 | 222 | 0.050 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 112 | 0.050 |
Why?
| | Multimodal Imaging | 1 | 2019 | 110 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 576 | 0.040 |
Why?
| | Delphi Technique | 1 | 2018 | 133 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 138 | 0.040 |
Why?
| | Half-Life | 1 | 2017 | 187 | 0.040 |
Why?
| | American Medical Association | 1 | 2017 | 20 | 0.040 |
Why?
| | Genomic Instability | 1 | 2017 | 40 | 0.040 |
Why?
| | Genome, Human | 1 | 2019 | 394 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 700 | 0.040 |
Why?
| | Needles | 1 | 2016 | 56 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 412 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 195 | 0.040 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 132 | 0.040 |
Why?
| | Retreatment | 1 | 2016 | 66 | 0.040 |
Why?
| | Platinum | 1 | 2016 | 29 | 0.040 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 259 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 95 | 0.040 |
Why?
| | Incidental Findings | 1 | 2016 | 81 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 369 | 0.040 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 28 | 0.040 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 30 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 199 | 0.040 |
Why?
| | Acute Disease | 1 | 2019 | 1000 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 454 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 420 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 575 | 0.040 |
Why?
| | Biomarkers | 2 | 2017 | 3501 | 0.040 |
Why?
| | Gene Duplication | 1 | 2015 | 67 | 0.040 |
Why?
| | Gene Frequency | 1 | 2017 | 572 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3049 | 0.040 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 117 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2016 | 348 | 0.040 |
Why?
| | Preoperative Care | 1 | 2017 | 339 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2015 | 325 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 221 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2893 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 662 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2021 | 960 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 768 | 0.030 |
Why?
| | Radiography | 1 | 2016 | 828 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 429 | 0.030 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 418 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1517 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2016 | 625 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 2053 | 0.030 |
Why?
| | Skin | 1 | 2016 | 702 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1831 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4906 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2016 | 3027 | 0.030 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2009 | 24 | 0.030 |
Why?
| | Protein Binding | 1 | 2016 | 2115 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 59 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1529 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 85 | 0.020 |
Why?
| | Reference Standards | 1 | 2008 | 194 | 0.020 |
Why?
| | Quality of Life | 1 | 2018 | 2136 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2019 | 1909 | 0.020 |
Why?
| | Rats | 1 | 2016 | 6387 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2008 | 170 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 5249 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 595 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 398 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2380 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2025 | 0.020 |
Why?
| | Reference Values | 1 | 2007 | 877 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2007 | 725 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2692 | 0.010 |
Why?
|
|
Lieu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|